Gemtuzumab Ozogamicin (GO) in children with de novo Acute Myeloid Leukemia (AML) improves Event-Free Survival (EFS) by reducing relapse risk - Results from the randomized phase III Children's Oncology Group (COG) trial, AAML0531

This article has no abstract
Epistemonikos ID: fb2778446ec9a6956bd498a42cf8bbc27c6056ef
First added on: Feb 05, 2025